Jens Bukh

Active 1992–2025

131
Papers
20,878
Citations
76
h-index
123
i10-index

Citations

Citations per year for Jens Bukh1992: 2 citations1993: 25 citations1994: 54 citations1995: 45 citations1996: 51 citations1997: 68 citations1998: 45 citations1999: 87 citations2000: 100 citations2001: 88 citations2002: 82 citations2003: 96 citations2004: 132 citations2005: 155 citations2006: 157 citations2007: 181 citations2008: 168 citations2009: 155 citations2010: 187 citations2011: 149 citations2012: 205 citations2013: 214 citations2014: 243 citations2015: 95 citations2016: 165 citations2017: 96 citations2018: 121 citations2019: 455 citations2020: 412 citations2021: 402 citations2022: 334 citations2023: 218 citations2024: 433 citations2025: 188 citations2026: 5 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,404 citing papers, 26.9% of this breakdownGermany: 402 citing papers, 7.7% of this breakdownUnited Kingdom: 381 citing papers, 7.3% of this breakdownChina: 339 citing papers, 6.5% of this breakdownFrance: 331 citing papers, 6.3% of this breakdownJapan: 210 citing papers, 4% of this breakdownItaly: 177 citing papers, 3.4% of this breakdownCanada: 160 citing papers, 3.1% of this breakdownAustralia: 148 citing papers, 2.8% of this breakdownDenmark: 129 citing papers, 2.5% of this breakdownSwitzerland: 103 citing papers, 2% of this breakdownSpain: 92 citing papers, 1.8% of this breakdown
0%26.9%Other 25.7%

Fields

  • Medicine76.9%
  • Biochemistry, Genetics and Molecular Biology8.2%
  • Agricultural and Biological Sciences6.5%
  • Immunology and Microbiology4.8%
  • Computer Science1.1%
  • Environmental Science0.7%
  • Other1.8%

Topics

  • Hepatitis C virus research18.8%
  • Hepatitis B Virus Studies12.2%
  • Liver Disease Diagnosis and Treatment6.1%
  • Monoclonal and Polyclonal Antibodies Research3.2%
  • SARS-CoV-2 and COVID-19 Research3.1%
  • Animal Virus Infections Studies2.8%
  • Other53.8%

Coauthors

All papers

Open in search
  1. ICTV Virus Taxonomy Profile: Flaviviridae

    Authors: , , , , , , , , , , - Journal of General Virology 2017 cited by 843

  2. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system

    Authors: , , , , , , , , , , , , , - Science Advances 2022 cited by 223

  3. Renaming of the genus Flavivirus to Orthoflavivirus and extension of binomial species names within the family Flaviviridae

    Authors: , , , , , , , , , , , , , , - Archives of Virology 2023 cited by 254

  4. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cyrielle Fougeroux, Constanze Heinzel, Rolf Fendel, Meral Esen, Peter G. Kremsner, Rob ter Heine, Heiman Wertheim, Manja Idorn, Søren R. Paludan, Alexander P. Underwood, Alekxander Binderup, Santseharay Ramírez, Jens Bukh, Max Soegaard, Sayit Mahmut Erdoğan, Tobias Gustavsson, Stine B. Clemmensen, Thor G. Theander, Ali Salanti, Mette Hamborg, Willem A. de Jongh, Matthew B. B. McCall, Morten A. Nielsen, Benjamin Mordmüller, Robert Dagil, Louise Goksøyr, Thomas Morgan Hulen, Christoph M. Janitzek, Daniel S. Jensen, Sune Justesen, Paul Khalifé, Andrea Kreidenweiss, Telma Lança, Olivia Lie-Andersen, Karina Teelen, Elena Ethel Vidal-Calvo - The Lancet Microbe 2023 cited by 40

  5. SARS‐CoV‐2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID‐19 vaccination

    Authors: , , , , , , , - Apmis 2023 cited by 54

  6. Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae

    Authors: , , , , , , , , , , - Journal of General Virology 2017 cited by 332

  7. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource

    Authors: , , , , , , - Hepatology 2013 cited by 1,352

  8. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 344

  9. Hepatitis C virus RNA is 5′-capped with flavin adenine dinucleotide

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 cited by 50

  10. Genomic analysis of the host response to hepatitis C virus infection

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2002 cited by 1,164

  11. Mouse models of acute and chronic hepacivirus infection

    Authors: , , , , , , , , , , , , , , - Science 2017 cited by 137

  12. Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy

    Authors: , , , , , , , , , , , , , , , , , , , - EBioMedicine 2022 cited by 38

  13. Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate

    Authors: , , , , , , , , , , , , - PLoS Pathogens 2012 cited by 217

  14. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication

    Authors: , , , , , , , , , , , , , , , - Antimicrobial Agents and Chemotherapy 2021 cited by 88

  15. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control

    Authors: - Journal of Hepatology 2016 cited by 238

  16. A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans

    Authors: , , , , , , , , , , , , , - PLoS ONE 2013 cited by 175

  17. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

    Authors: , , , , , , , , , , , - Virus Research 2018 cited by 170

  18. Genetic and structural insights into broad neutralization of hepatitis C virus by human V H 1-69 antibodies

    Authors: , , , , , , , , , , , , - Science Advances 2019 cited by 99

  19. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design

    Authors: , , , , , , , , , , , , , , , , - PLoS Pathogens 2019 cited by 60

  20. Toward a vaccine against hepatitis C virus

    Authors: , , - Science 2023 cited by 22

  21. Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *

    Authors: , , , , , , , , , , , , , , , , , , , , , - Hepatology 2005 cited by 1,505

  22. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

    Authors: , , , , , , , , , , , , , - Scientific Reports 2021 cited by 97

  23. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro

    Authors: , , , , , , , , , , , , - Antimicrobial Agents and Chemotherapy 2021 cited by 46

  24. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

    Authors: , , , , , , , , , , , , , , , , - EBioMedicine 2023 cited by 25